Larazotide Evidence Guide
Larazotide has Phase 3 data in celiac disease as a tight junction regulator, showing statistically significant reduction in GI symptoms even on a gluten-free diet. While its primary Phase 3 trial missed its primary endpoint, secondary endpoints were positive and a new trial is ongoing. For tight junction biology and celiac disease research, it is the most advanced clinical candidate in its mechanistic class.
Our Take
Larazotide has Phase 3 data in celiac disease as a tight junction regulator, showing statistically significant reduction in GI symptoms even on a gluten-free diet. While its primary Phase 3 trial missed its primary endpoint, secondary endpoints were positive and a new trial is ongoing. For tight junction biology and celiac disease research, it is the most advanced clinical candidate in its mechanistic class.
- Evidence context
- Celiac disease symptom management, tight junction permeability research, intestinal barrier restoration
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Reported research reference: 0.5mg oral three times daily before meals (Phase 3 dosing)
Benefits and Evidence
- Celiac Disease Symptom Reduction: Level B, includes human evidence - Phase 2 trials demonstrated significant reduction in celiac disease symptom severity scores including abdominal pain, bloating, and diarrhea in patients on a gluten-free diet with inadvertent gluten exposure.
- Intestinal Permeability Improvement: Level B, includes human evidence - Paterson et al. (2007, Aliment Pharmacol Ther) Phase II RCT (n=86 celiac patients) showed larazotide 0.25 mg TID reduced lactulose-to-mannitol ratio by 70% after gluten challenge vs. placebo (p=0.008); Leffler et al. (2012, Gastroenterology) Phase IIb (n=342) confirmed reduced intestinal permeability at the same dose.
- Gluten-Induced Immune Activation Reduction: Level C, includes human evidence - Some evidence of reduced anti-tissue transglutaminase antibody levels and decreased inflammatory marker elevation following gluten exposure in treated patients.
Side Effects and Warnings
- Generally well-tolerated in clinical trials
- Headache
- Urinary tract infection
- Nausea
- Upper respiratory tract infection
- Adverse event profile similar to placebo in most studies
- Not yet FDA-approved; Phase 3 trials ongoing
- Not a substitute for a gluten-free diet in celiac disease
Research Dosage References
- <strong>Oral</strong> - 0.5 mg - Three times daily (before meals) - Optimal dose identified in Phase 2b dose-ranging study. Taken 15 minutes before each meal to be present in the gut lumen during gluten exposure.
- <strong>Oral</strong> - 0.25-1.0 mg - Three times daily - Dose range studied in clinical trials. The 0.5 mg TID dose showed the best efficacy-to-tolerability ratio.
Mechanism of Action
Larazotide prevents intestinal barrier dysfunction through: 1. Zonulin pathway antagonism: Blocks the zonulin receptor, preventing zonulin-mediated tight junction disassembly triggered by gluten-derived gliadin peptides. 2. Tight junction stabilization: Maintains the structural integrity of claudin and occludin proteins in intestinal epithelial tight junction complexes. 3. Actin cytoskeleton preservation: Prevents myosin light chain kinase (MLCK) activation and the subsequent actin-myosin contraction that opens paracellular pathways. 4. Permeability reduction: By maintaining tight junction integrity, reduces paracellular passage of immunogenic gluten peptides, bacterial antigens, and other luminal contents. 5. Local GI action: Acts locally in the intestinal lumen with minimal systemic absorption.
Legal Status
Larazotide acetate is an investigational drug in Phase 3 clinical trials. Not yet approved by the FDA or other regulatory agencies. Fast Track designation granted by the FDA for celiac disease. Developed by 9 Meters Biopharma (formerly Innovate Biopharmaceuticals).
Primary Sources
- Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a Phase 2b study. Gastroenterology, 2015.
- Effect of larazotide acetate on intestinal permeability in celiac disease. Aliment Pharmacol Ther, 2007.
- Larazotide acetate and the tight junction: a novel therapeutic approach for celiac disease. Expert Opin Investig Drugs, 2012.
Quick Answers
Where is the strongest evidence for Larazotide?
Larazotide has Phase 3 data in celiac disease as a tight junction regulator, showing statistically significant reduction in GI symptoms even on a gluten-free diet. While its primary Phase 3 trial missed its primary endpoint, secondary endpoints were positive and a new trial is ongoing. For tight junction biology and celiac disease research, it is the most advanced clinical candidate in its mechanistic class. Evidence context: Celiac disease symptom management, tight junction permeability research, intestinal barrier restoration.
What are the main side effects of Larazotide?
Larazotide side effects and warning signals include Generally well-tolerated in clinical trials, Headache, Urinary tract infection, Nausea, and Upper respiratory tract infection.
What evidence level is Larazotide?
Larazotide is rated Level B; the listed research status is Phase 3.